<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39309610</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2590-1362</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Vaccine: X</Title><ISOAbbreviation>Vaccine X</ISOAbbreviation></Journal><ArticleTitle>Kinetics of humoral and cellular immune responses 5 months post-COVID-19 booster dose by immune response groups at the peak immunity phase: An observational historical cohort study using the Fukushima vaccination community survey.</ArticleTitle><Pagination><StartPage>100553</StartPage><MedlinePgn>100553</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100553</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jvacx.2024.100553</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Understanding the waning of immunity after booster vaccinations is important to identify which immune-low populations should be prioritized.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We investigated longitudinal cellular and humoral immunity after the third vaccine dose in both high- and low-cellular and humoral immunity groups at the peak immunity phase after the booster vaccination in a large community-based cohort. Blood samples were collected from 1045 participants at peak (T1: median 54 days post-third dose) and decay (T2: median 145 days post-third dose) phases to assess IgG(S), neutralizing activity, and ELISpot responses. Participants were categorized into high/low ELISpot/IgG(S) groups at T1. Cellular and humoral responses were tracked for approximately five months after the third vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In total, 983 participants were included in the cohort. IgG(S) geometric mean fold change between timepoints revealed greater waning in the &gt;79 years age group (T2/T1 fold change: 0.27) and higher IgG(S) fold change in the low-ELISpot group at T1 (T2/T1 fold change: 0.32-0.33) than in the other groups, although ELISpot geometric mean remained stable.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Antibody level of those who did not respond well to third dose vaccination waned rapidly than those who responded well. Evidence-based vaccine strategies are essential in preventing potential health issues caused by vaccines, including side-effects.</AbstractText><CopyrightInformation>© 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kobashi</LastName><ForeName>Yurie</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawamura</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Isotope Science Center, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimazu</LastName><ForeName>Yuzo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneko</LastName><ForeName>Yudai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical &amp; Biological Laboratories Co., Ltd, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishikawa</LastName><ForeName>Yoshitaka</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sugiyama</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Isotope Science Center, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tani</LastName><ForeName>Yuta</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medical Governance Research Institute, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakayama</LastName><ForeName>Aya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Isotope Science Center, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoshida</LastName><ForeName>Makoto</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Medical Governance Research Institute, Minato-ku, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zho</LastName><ForeName>Tianchen</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamamoto</LastName><ForeName>Chika</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Hiroaki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takita</LastName><ForeName>Morihito</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wakui</LastName><ForeName>Masatoshi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kodama</LastName><ForeName>Tatsuhiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsubokura</LastName><ForeName>Masaharu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Radiation Health Management, Fukushima Medical University School of Medicine, Fukushima City, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of General Internal Medicine, Hirata Central Hospital, Hirata, Ishikawa District, Fukushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>General Incorporated Association for Comprehensive Disaster Health Management Research Institute, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vaccine X</MedlineTA><NlmUniqueID>101748769</NlmUniqueID><ISSNLinking>2590-1362</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Booster dose vaccine effectiveness</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cellular immunity</Keyword><Keyword MajorTopicYN="N">Humoral immunity</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Kaneko is employed by Medical &amp; Biological Laboratories, Co. (MBL, Tokyo, Japan). MBL imported the testing material used in this research. Kaneko participated in the testing process but was not involved in the research design and analysis. Kobashi and Tsubokura received a grant from Pfizer Health Research Foundation for research unrelated to this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39309610</ArticleId><ArticleId IdType="pmc">PMC11416657</ArticleId><ArticleId IdType="doi">10.1016/j.jvacx.2024.100553</ArticleId><ArticleId IdType="pii">S2590-1362(24)00126-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Williams N., et al. Assessment of racial and ethnic disparities in access to COVID-19 vaccination sites in Brooklyn, NY. JAMA Netw Open. 2021;4</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8214153</ArticleId><ArticleId IdType="pubmed">34143195</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida M., et al. Factors associated with COVID-19 vaccine booster hesitancy: a retrospective cohort study, Fukushima vaccination community survey. Vaccines (Basel) 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9032295</ArticleId><ArticleId IdType="pubmed">35455264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobashi Y., et al. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine. PLoS One. 2022;17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9187057</ArticleId><ArticleId IdType="pubmed">35687563</ArticleId></ArticleIdList></Reference><Reference><Citation>Riad A., et al. COVID-19 vaccines safety tracking (CoVaST): protocol of a multi-center prospective cohort study for active surveillance of COVID-19 vaccines’ side effects. Int J Environ Res Public Health. 2021;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8345554</ArticleId><ArticleId IdType="pubmed">34360156</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond M., et al. SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies. Res Sq. 2021</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058618</ArticleId><ArticleId IdType="pubmed">33664494</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldberg Y., et al. Waning immunity after the BNT162b2 vaccine in Israel. N Engl J Med. 2021;385</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8609604</ArticleId><ArticleId IdType="pubmed">34706170</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaxman A., et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) Lancet. 2021;398:981–990.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8409975</ArticleId><ArticleId IdType="pubmed">34480858</ArticleId></ArticleIdList></Reference><Reference><Citation>Shroff R.T., et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27:2002–2011.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9004706</ArticleId><ArticleId IdType="pubmed">34594036</ArticleId></ArticleIdList></Reference><Reference><Citation>Shroff RT et al. Immune responses to COVID-19 mRNA vaccines in patients with solid tumors on active, immunosuppressive cancer therapy. medRxiv; 2021.</Citation></Reference><Reference><Citation>Re D., et al. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat. Commun. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844396</ArticleId><ArticleId IdType="pubmed">35165284</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert L., et al. Immunogenicity of COVID-19 vaccinations in hematological patients: 6-month follow-up and evaluation of a 3rd vaccination. Cancers (Basel) 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9032993</ArticleId><ArticleId IdType="pubmed">35454867</ArticleId></ArticleIdList></Reference><Reference><Citation>Morawska M. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur J Haematol. 2022;108:91–98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8652891</ArticleId><ArticleId IdType="pubmed">34717004</ArticleId></ArticleIdList></Reference><Reference><Citation>Reindl-Schwaighofer R., et al. Comparison of SARS-CoV-2 antibody response 4 weeks after homologous vs heterologous third vaccine dose in kidney transplant recipients: a randomized clinical trial. JAMA Intern Med. 2022;182:165–171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8689434</ArticleId><ArticleId IdType="pubmed">34928302</ArticleId></ArticleIdList></Reference><Reference><Citation>Yahav D., et al. Immune response to third dose BNT162b2 COVID-19 vaccine among kidney transplant recipients-a prospective study. Transpl Int. 2022;35</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9068869</ArticleId><ArticleId IdType="pubmed">35529596</ArticleId></ArticleIdList></Reference><Reference><Citation>Meshram H.S., et al. Humoral and cellular response of COVID-19 vaccine among solid organ transplant recipients: a systematic review and meta-analysis. Transpl Infect Dis. 2022;24</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9538045</ArticleId><ArticleId IdType="pubmed">35924679</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira V.H., et al. Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings. Nat Commun. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9352686</ArticleId><ArticleId IdType="pubmed">35927279</ArticleId></ArticleIdList></Reference><Reference><Citation>Assawakosri S., et al. Neutralizing activities against the omicron variant after a heterologous booster in healthy adults receiving two doses of CoronaVac vaccination. J Infect Dis. 2022;226:1372–1381.</Citation><ArticleIdList><ArticleId IdType="pubmed">35267040</ArticleId></ArticleIdList></Reference><Reference><Citation>Pulvirenti F., et al. B cell response induced by SARS-CoV-2 infection is boosted by the BNT162b2 vaccine in primary antibody deficiencies. Cells. 2021;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8616496</ArticleId><ArticleId IdType="pubmed">34831138</ArticleId></ArticleIdList></Reference><Reference><Citation>Arroyo-Sánchez D., et al. Immunogenicity of anti-SARS-CoV-2 vaccines in common variable immunodeficiency. J Clin Immunol. 2022;42:240–252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8596355</ArticleId><ArticleId IdType="pubmed">34787773</ArticleId></ArticleIdList></Reference><Reference><Citation>Thümmler L., et al. Cellular and humoral immunity after the third vaccination against SARS-CoV-2 in hematopoietic stem-cell transplant recipients. Vaccines (Basel) 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9230894</ArticleId><ArticleId IdType="pubmed">35746580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang K., Wei Z., Wu X. Impaired serological response to COVID-19 vaccination following anticancer therapy: a systematic review and meta-analysis. J Med Virol. 2022;94:4860–4868.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349696</ArticleId><ArticleId IdType="pubmed">35750492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mrak D., et al. Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study. Ann Rheum Dis. 2022;81:1750–1756.</Citation><ArticleIdList><ArticleId IdType="pubmed">35977809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehrnbecher T., et al. Longitudinal immune response to 3 doses of messenger RNA vaccine against coronavirus disease 2019 (COVID-19) in pediatric patients receiving chemotherapy for cancer. Clin Infect Dis. 2022;76:e510–e513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9384602</ArticleId><ArticleId IdType="pubmed">35901198</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzolini E., et al. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. Life Sci Alliance. 2022;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8860093</ArticleId><ArticleId IdType="pubmed">35169017</ArticleId></ArticleIdList></Reference><Reference><Citation>Dayam R.M., et al. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases. JCI Insight. 2022;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9220925</ArticleId><ArticleId IdType="pubmed">35471956</ArticleId></ArticleIdList></Reference><Reference><Citation>Sand IK et al. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy. medRxiv; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9794520</ArticleId><ArticleId IdType="pubmed">36628884</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J., et al. Immunogenicity of BNT162b2 vaccine against the Alpha and Delta variants in immunocompromised patients with systemic inflammatory diseases. Ann Rheum Dis. 2022;81:720–728.</Citation><ArticleIdList><ArticleId IdType="pubmed">35022159</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon B., et al. SARS-CoV-2 antibody and T cell response after a third vaccine dose in hemodialysis patients compared with healthy controls. Vaccines. 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9145549</ArticleId><ArticleId IdType="pubmed">35632450</ArticleId></ArticleIdList></Reference><Reference><Citation>Karakizlis H., et al. Immunogenicity and reactogenicity of homologous mRNA-based and vector-based SARS-CoV-2 vaccine regimens in patients receiving maintenance dialysis. Clin Immunol. 2022;236</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8875769</ArticleId><ArticleId IdType="pubmed">35227871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallantyre E.C., et al. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Mult Scler Relat Disord. 2022;64</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166227</ArticleId><ArticleId IdType="pubmed">35700625</ArticleId></ArticleIdList></Reference><Reference><Citation>Peled Y., et al. Kinetics of cellular and humoral responses to third BNT162B2 COVID-19 vaccine over six months in heart transplant recipients – implications for the omicron variant. J Heart Lung Transplant. 2022;41:1417–1425.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128305</ArticleId><ArticleId IdType="pubmed">35710484</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobudic S., et al. Immune response after mRNA COVID-19 vaccination in lung transplant recipients: a 6-month follow-up. Vaccines (Basel) 2022;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9318026</ArticleId><ArticleId IdType="pubmed">35891294</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradini P., et al. Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study. Clin Infect Dis. 2022;76:e426–e438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213871</ArticleId><ArticleId IdType="pubmed">35607769</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidov Y., et al. A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients. J Hepatol. 2022;77:702–709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9015954</ArticleId><ArticleId IdType="pubmed">35452692</ArticleId></ArticleIdList></Reference><Reference><Citation>Charmetant X., et al. Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients. Sci Transl Med. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939774</ArticleId><ArticleId IdType="pubmed">35103481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stumpf J., et al. Anti-SARS-CoV-2 revaccination success in kidney transplant recipients with no initial humoral response is linked to primary vaccine type. Front Med (Lausanne) 2022;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9289185</ArticleId><ArticleId IdType="pubmed">35860743</ArticleId></ArticleIdList></Reference><Reference><Citation>Jotschke S., et al. Longitudinal humoral and cellular immune responses following SARS-CoV-2 vaccination in patients with myeloid and lymphoid neoplasms compared to a reference cohort: results of a prospective trial of the East German study group for hematology and oncology (OSHO) Cancers. 2022;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8946280</ArticleId><ArticleId IdType="pubmed">35326695</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Health. LaW. Coronavirus (COVID-19); 2023. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000164708_00079.html.</Citation></Reference><Reference><Citation>Kobashi Y., et al. Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: a historical cohort study. Int Immunopharmacol. 2021;98</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8200307</ArticleId><ArticleId IdType="pubmed">34246041</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimazu Y., et al. Mental distress in a clinical nurse due to a false-positive COVID-19 antibody test result during the COVID-19 epidemic in Japan: a case report. Clin Case Rep. 2021;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8123730</ArticleId><ArticleId IdType="pubmed">34026162</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobashi Y., et al. Peak IgG antibody titers against SARS-CoV-2 spike protein following immunization with the Pfizer/BioNTech BNT162b2 vaccine. Fukushima J Med Sci. 2022;68:67–70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9071351</ArticleId><ArticleId IdType="pubmed">35228456</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobashi Y., et al. Maturing of public-private-people partnership (4P): lessons from 4P for triple disaster and subsequently COVID-19 pandemic in Fukushima. J Glob Health. 2022;12</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9172965</ArticleId><ArticleId IdType="pubmed">35674274</ArticleId></ArticleIdList></Reference><Reference><Citation>Uwamino Y., et al. Dynamics of antibody titers and cellular immunity among Japanese healthcare workers during the 6 months after receiving two doses of BNT162b2 mRNA vaccine. Vaccine. 2022;40:4538–4543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212396</ArticleId><ArticleId IdType="pubmed">35718591</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R., et al. Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. Nat Med. 2022;28:1486–1490.</Citation><ArticleIdList><ArticleId IdType="pubmed">35468276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.M., et al. Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. Front Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10073433</ArticleId><ArticleId IdType="pubmed">37033936</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli C.M., et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung S., et al. The generation of stem cell-like memory cells early after BNT162b2 vaccination is associated with durability of memory CD8+ T cell responses. Cell Rep. 2022;40</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9263810</ArticleId><ArticleId IdType="pubmed">35839774</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray C.E., et al. Cellular and humoral immunogenicity of the COVID-19 vaccine and COVID-19 disease severity in individuals with immunodeficiency. Front Immunol. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10080028</ArticleId><ArticleId IdType="pubmed">37033955</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>